Harm Reduction Therapeutics
  • Our Story
  • OTC RiVive®
  • Why 3 mg?
  • Contact Us
  • Login
  • My Account
  • Buy Now
  • What Is Harm Reduction
  • Resources
  • News
  • FAQ
  • What Is Harm Reduction?
  • Resources
  • News
  • FAQ
Drug Intervention Institute partners with Harm Reduction Therapeutics to provide low-cost life-saving RiVive™ 3 mg naloxone nasal spray inside ONEbox™

Drug Intervention Institute partners with Harm Reduction Therapeutics to provide low-cost life-saving RiVive™ 3 mg naloxone nasal spray inside ONEbox™

by Brian Shim | Mar 1, 2024 | News

Higher naloxone doses have no impact on overdose survival, study shows

Higher naloxone doses have no impact on overdose survival, study shows

by Brian Shim | Feb 8, 2024 | News

Open Society Supports an Innovative Model to Make Naloxone Easier to Access Amidst the U.S. Overdose Crisis

Open Society Supports an Innovative Model to Make Naloxone Easier to Access Amidst the U.S. Overdose Crisis

by Brian Shim | Dec 12, 2023 | News

Partnership to Save Lives: Harm Reduction Therapeutics to donate 200,000 RiVive™ naloxone doses to Remedy Alliance for free distribution

Partnership to Save Lives: Harm Reduction Therapeutics to donate 200,000 RiVive™ naloxone doses to Remedy Alliance for free distribution

by Brian Shim | Aug 17, 2023 | News

FDA APPROVAL OF RiVIVE™ IS A CRITICAL MILESTONE IN MAKING EMERGENCY TREATMENT OF OPIOID OVERDOSE MORE WIDELY AVAILABLE

FDA APPROVAL OF RiVIVE™ IS A CRITICAL MILESTONE IN MAKING EMERGENCY TREATMENT OF OPIOID OVERDOSE MORE WIDELY AVAILABLE

by Brian Shim | Aug 1, 2023 | News

« Older Entries
  • Contact Us
  • Privacy Policy
  • Accessibility
  • FAQ
  • Follow
  • Follow

© Copyright 2025 Harm Reduction Therapeutics, Inc. All Rights Reserved. To report Adverse Events contact: customercare@harmreductiontherapeutics.org.